Multivalent metal salts of boronic acids

Details Multivalent metal salts of boronic acids Multivalent metal salts of boronic acids

2006-09-26

2006-09-26

Campell, Bruce R. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S064000, C546S013000, C548S405000

Reexamination Certificate

active

07112572

ABSTRACT:
Salts of a pharmaceutically acceptable divalent metal and an organoboronic acid drug. Examples of such metals are calcium, magnesium and zinc. The organoboronic acid drug may be a boropeptide protease inhibitor. The salts may be formulated in oral dosage form.

REFERENCES:
patent: 4499082 (1985-02-01), Shenvi et al.
patent: 4701545 (1987-10-01), Matteson et al.
patent: 4935493 (1990-06-01), Bachovchin et al.
patent: 4963655 (1990-10-01), Kinder et al.
patent: 5169841 (1992-12-01), Kleeman et al.
patent: 5187157 (1993-02-01), Kettner et al.
patent: 5444049 (1995-08-01), de Nanteuil et al.
patent: 5462964 (1995-10-01), Fevig et al.
patent: 5563127 (1996-10-01), Amparo et al.
patent: 5574014 (1996-11-01), Claeson et al.
patent: 5585360 (1996-12-01), de Nanteuil et al.
patent: 5639739 (1997-06-01), Dominguez et al.
patent: 5658885 (1997-08-01), Lee et al.
patent: 5681978 (1997-10-01), Matteson et al.
patent: 5731439 (1998-03-01), Carini et al.
patent: 5780454 (1998-07-01), Adams et al.
patent: 5814622 (1998-09-01), de Nanteuil et al.
patent: 6066730 (2000-05-01), Adams et al.
patent: 6083903 (2000-07-01), Adams et al.
patent: 6114308 (2000-09-01), Claeson et al.
patent: 6297217 (2001-10-01), Adams et al.
patent: 6313096 (2001-11-01), Claeson et al.
patent: 6417174 (2002-07-01), Shoichet et al.
patent: 6617317 (2003-09-01), Adams et al.
patent: 6713446 (2004-03-01), Gupta et al.
patent: 6747150 (2004-06-01), Adams et al.
patent: 2004/0138175 (2004-07-01), Madge et al.
patent: 2004/0147453 (2004-07-01), Deadman et al.
patent: 2005/0119226 (2005-06-01), Walter et al.
patent: 2005/0176651 (2005-08-01), Madge et al.
patent: 2005/0282757 (2005-12-01), Combe-Marzelle et al.
patent: 2005/0288253 (2005-12-01), Madge et al.
patent: 0 235 692 (1987-02-01), None
patent: 0471651 (1992-02-01), None
patent: 0 599 633 (1993-11-01), None
patent: WO 89/09612 (1989-10-01), None
patent: WO 92/07869 (1992-05-01), None
patent: WO 94/21650 (1994-09-01), None
patent: WO 94/21668 (1994-09-01), None
patent: WO 94/25049 (1994-11-01), None
patent: WO 95/09634 (1995-04-01), None
patent: WO 95/09858 (1995-04-01), None
patent: WO 95/09859 (1995-04-01), None
patent: WO 96/12499 (1996-05-01), None
patent: WO 96/13266 (1996-05-01), None
patent: WO 96/20689 (1996-07-01), None
patent: WO 97/05161 (1997-02-01), None
patent: WO 98/00443 (1998-01-01), None
patent: WO 98/31688 (1998-07-01), None
patent: WO 99/26652 (1999-06-01), None
patent: WO 00/35904 (2000-06-01), None
patent: WO 00/35905 (2000-06-01), None
patent: WO 00/41715 (2000-07-01), None
patent: WO 01/02424 (2001-01-01), None
patent: WO 01/41796 (2001-06-01), None
patent: WO 02/36157 (2002-05-01), None
patent: WO 02/059130 (2002-08-01), None
patent: WO 02/059131 (2002-08-01), None
patent: WO 03/007984 (2003-01-01), None
Skordalakes et al. Crystallographic Structures of Human a-Thrombin Complexed to Peptide Boronic Acids Lacking a Positive Charge at P1. Evidence of Novel Interactions. J Am Chem Soc 1997, vol. 119, pp. 9935-9936.
Deadman et al. Characterization of a Class of Peptide Boronates with Neutral P1 Side Chains as Highly Selective Inhibitors of Thrombin. J Med Chem 1995, vol. 38, pp. 1511-1522.
Claeson et al. Benzyloxycarbonyl-D-Phe-Pro-methoxypropylboroglycine: a novel inhibitor of thrombin with high selectivity containing a neutral side chain at the P1 position. Biochem J. 1993, vol. 290, pp. 309-312.
Claeson et al.,Thromb Haemostas, vol. 65, p. 1289, 1991.
Claeson et al., “Novel peptide mimetics as highly efficient inhibitors of thrombin based on modified D-Phe-Pro-Arg sequences,”in Peptides, Chemistry and Biology, Smith J A, Rivier J E, Eds., Escom: Leidenpp. 824-825, 1992.
Claeson et al.,Biochem J. 290:309-312, 1993.
Claeson et al.,The Design of Synthetic Inhibitors of Thrombin340:83-89, 1993.
Claeson,Blood Coagulation and Fibrinolysis5:411-436, 1994.
Coburn,Exp. Opin. Ther. Patents11(5):721-738, 2001.
Contreras et al.,J. Org. Chem. 246:213-217, 1983.
Deadman et al.,J. Medicinal Chemistry38:1511-1522, 1995.
Deadman et al.,J. Enzyme Inhibition9:29-41, 1995.
Elgendy et al.,Thromb Haemostas65:775, 1991.
Elgendy et al.,Tetrahedron Letters33(29):4209-4212, 1992.
Elgendy et al.,The Design of Synthetic Inhibitors of Thrombin340:173-178, 1993.
Elgendy et al.,Tetrahedron50(12):3803-3812, 1994.
Esmail et al.,Thrombosis and Haemostasis6:1318, 1995.
Esmail et al.,Thrombosis and Haemostasis5:91-92, 1997.
Esmail et al.,Thrombosis and Haemostasis5:498-499, 1997.
Gerrard et al.,Thrombosis and Haemostasis6:1307, 1995.
Gustafsson et al.,Thrombosis Research101:171-181, 2001.
Katz et al.,Biochemistry34(26):8264-8280, 1995.
Martichonok et al.,J. Am. Chem. Soc. 118:950-958, 1996.
Matt et al.,Bioorg. Med. Chem. 8:2291-2303, 2000.
Matteson,Chem. Rev. 89:1535-1551, 1989.
Matteson et al.,J. Org. Chem. 61:6047-6051, 1996.
Metternich et al.,Naunyn-Schmiedeberg's Arch Pharmocol97:345, 1992.
Philipp et al.,The Design of Synthetic Inhibitors of Thrombin340:67-77, 1993.
Rewinkel et al.,Current Pharmaceutical Design5:1043-1075, 1999.
Saitoh et al.,Pharmaceutical Research16(11):1786-1789, 1999.
Sanderson et al.,Current Medicinal Chemistry5:289-304, 1998.
Skordalakes et al.,Biochemistry37(41):14420-14427, 1998.
Spencer et al.,Tetrahedron58:1551-1556, 2002.
Stahl et al.,Handbook of Pharmaceutical Salts Properties, Selection, and Use, Verlag Helvetica Chimica Acta, Postfach, CH-8042 Züirch, Switzerland, 2002.
Tapparelli et al.,The Journal of Biological Chemistry268(7):4734-4741, 1993.
Tapparelli et al.,Trends Pharmacol. Sci. 14:366-376, 1993.
Trigen Limited,TRI 50b Non Confidential Informationpp. 1-12, Jul. 2002.
Trigen Limited, “Looking for a career in Biotechnology?” poster exhibited at XVIIth International Symposium on Medicinal Chemistry, Barcelona, Spain, Sep. 5, 2002.
Tripathy et al.,Synthesispp. 200-206, 1990.
Wu et al.,Journal of Pharmaceutical Sciences89(6):758-765, Jun. 2000.
Yang et al.,Pharmaceutical Research16(9):1331-1343, 1999.
Yang et al.,Medicinal Research Reviews23(3):346-368, 2003.
Bastin et al., “Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities,”Organic Process Research&Development4:427-435, 2000.
Berge et al., “Pharmaceutical Salts,”Journal of Pharmaceutical Sciences66(1) :1-19, 1977.
Brikh et al., “Boronated thiophenols: a preparation of 4-mercaptophenylboronic acid and derivatives,”Journal of Organometallic Chemistry581:82-86, 1999.
Davies et al., “Peroxides of Elements other than Carbon. Part XII. The Autoxidation of Optically Active 1-Phenylethylboronic Acid,”J Chem Socpp. 17-22, 1967.
Elgendy et al., “Design of a novel class of bifunctional thrombin inhibitors, synthesised by the first application of peptide boronates of solid phase chemistry,”Tetrahedron Letters38(18):3305-3308, 1997.
Hsiao et al., “A Facile Synthesis oftert-Butyl 2-[Benzyloxycarbonyl)amino]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propionate: An Orthogonally Protected Boronic Acid Analog of Aspartic Acid,”Synthesis7:1043-1046, 1998.
Kettner et al., “Inhibition of the Serine Proteases Leukocyte Elastase, Pancreatic Elastase, Cathepsin G, and Chymotrypsin by Peptide Boronic Acids,”The Journal of Biological Chemistry259(24)15106-15114, 1984.
Kettner et al., “The Selective Inhibition of Thrombin of Peptides of Boroarginine,”The Journal of Biological Chemistry265(30):18289-18297, 1990.
Lappert, “Organic Compounds of Boron,”Chem. Review56:959-1064, 1956.
Martichonok et al., “Cysteine Proteases such as Papain are not Inhibited by Substrate Analogue Peptidyl Boronic Acids,”Bioorganic and Medicinal Chemistry5(4):679-684, 1997.
Snyder et al., “Organoboron Compounds, and the Study of Reaction Mechanisms. Primary Aliphatic Boronic Acids,”Am Chem Soc60:105-111, 1938.
Snyder et al., “Aryl Boronic Acids. II. Aryl Boronic Anhydrides and their Amine Complexes,”Am Chem Soc80:3611-3615, 1958.
Wityak et al., “Synthesis of Thrombin Inhibitor DuP 714,”J.

Affiliated with

Also associated with

Rating

Multivalent metal salts of boronic acids does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Multivalent metal salts of boronic acids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multivalent metal salts of boronic acids will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3580493